Dr. Mitchell on Colorectal Cancer Treatment Options

Edith Mitchell, MD, FACP
Published: Tuesday, Sep 10, 2013

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, talks about the growing number of drugs and regimens for patients with colorectal cancer.

Mitchell says the approval of aflibercept adds to the growing list of drugs for patients with colorectal cancer.

In 1996, Mitchell says, 5-gluorouracil was the only drug that showed benefit for patients with metastatic colorectal cancer. Now, as a variety of drugs are available to patients, doctors can strive for the best quality of life possible.

As the number of drugs has increased, so has the improvement of survival for patients with colorectal cancer, Mitchell says.
Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, talks about the growing number of drugs and regimens for patients with colorectal cancer.

Mitchell says the approval of aflibercept adds to the growing list of drugs for patients with colorectal cancer.

In 1996, Mitchell says, 5-gluorouracil was the only drug that showed benefit for patients with metastatic colorectal cancer. Now, as a variety of drugs are available to patients, doctors can strive for the best quality of life possible.

As the number of drugs has increased, so has the improvement of survival for patients with colorectal cancer, Mitchell says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x